Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 155

Sort by

Sort Order Select

Journal Articles

Data mining for second malignancies after CAR-T

Helen E. Heslop

Blood (2024) 143 (20): 2023–2024.

https://doi.org/10.1182/blood.2024024446

Published: 2024

Journal Articles

Antitumor efficacy and safety of unedited autologous CD5.CAR T cells in relapsed/refractory mature T-cell lymphomas

Blood (2024) 143 (13): 1231–1241.

https://doi.org/10.1182/blood.2023022204

Published: 2024

Includes: Supplemental data

Journal Articles

Introduction to a How I Treat series on emergent CAR T-cell toxicities

Helen E. Heslop

Blood (2023) 141 (20): 2405–2407.

https://doi.org/10.1182/blood.2023020228

Published: 2023

Journal Articles

Engineering T cells to suppress acute GVHD and leukemia relapse after allogeneic hematopoietic stem cell transplantation

Feiyan Mo, Norihiro Watanabe, Kayleigh I. Omdahl, Phillip M. Burkhardt, Xiaoyun Ding, Eiko Hayase, Angela Panoskaltsis-Mortari, Robert R. Jenq, Helen E. Heslop, Leslie S. Kean, Malcolm K. Brenner, Victor Tkachev, Maksim Mamonkin

Blood (2023) 141 (10): 1194–1208.

https://doi.org/10.1182/blood.2022016052

Published: 2023

Includes: Supplemental data

Journal Articles

Introduction to a review series on banked allogeneic immune effector cells

Helen E. Heslop

Blood (2023) 141 (8): 811–812.

https://doi.org/10.1182/blood.2023019604

Published: 2023

Journal Articles

CD30.CAR-Modified Epstein-Barr Virus-Specific T Cells (CD30.CAR EBVSTs) Provide a Safe and Effective Off-the-Shelf Therapy for Patients with CD30-Positive Lymphoma

Blood (2022) 140 (Supplement 1): 412–414.

https://doi.org/10.1182/blood-2022-160244

Published: 2022

Journal Articles

Phase 1b/2 Study of Autologous CD30.CAR-T Cells in Combination with Nivolumab in Patients with Relapsed or Refractory Classical Hodgkin Lymphoma after Failure of Frontline Therapy (ACTION)

Matthew Mei, Sairah Ahmed, Amer Beitinjaneh, Natalie S. Grover, Carlos A. Ramos, Khong Bee Kang, Paul I. Nadler, Aung Myo, Ivan D. Horak, Helen E. Heslop

Blood (2022) 140 (Supplement 1): 12728–12730.

https://doi.org/10.1182/blood-2022-157131

Published: 2022

Journal Articles

Ultrasensitive Circulating Tumor DNA (ctDNA) Dynamics after Autologous CD30.CAR-T Cell Therapy for Relapsed or Refractory (r/r) Classical Hodgkin Lymphoma (CHARIOT Trial)

David M. Kurtz, Sairah Ahmed, Cheuk Ka Tong, Matthew Mei, Cliff Ding, Ian W. Flinn, Peter A. Riedell, Gregory J. Hogan, Andre Schultz, Jacob J. Chabon, Helen E. Heslop, Aung Myo, Ash A. Alizadeh, Ivan D. Horak

Blood (2022) 140 (Supplement 1): 2378–2380.

https://doi.org/10.1182/blood-2022-162150

Published: 2022

Journal Articles

Updated Results and Correlative Analysis: Autologous CD30.CAR-T-Cell Therapy in Patients with Relapsed or Refractory Classical Hodgkin Lymphoma (CHARIOT Trial)

Sairah Ahmed, Ian W. Flinn, Matthew Mei, Peter A. Riedell, Philippe Armand, Natalie S. Grover, Renu Balyan, Cliff Ding, Aung Myo, Ivan D. Horak, Helen E. Heslop

Blood (2022) 140 (Supplement 1): 7496–7497.

https://doi.org/10.1182/blood-2022-158869

Published: 2022

Journal Articles

Tumor-intrinsic causes of CAR-T failure

Helen E. Heslop

Blood (2022) 140 (5): 414–415.

https://doi.org/10.1182/blood.2022016851

Published: 2022

Journal Articles

Long-term follow-up for the development of subsequent malignancies in patients treated with genetically modified IECs

Blood (2022) 140 (1): 16–24.

https://doi.org/10.1182/blood.2022015728

Published: 2022

Journal Articles

Donor-derived multiple leukemia antigen–specific T-cell therapy to prevent relapse after transplant in patients with ALL

Blood (2022) 139 (17): 2706–2711.

https://doi.org/10.1182/blood.2021014648

Published: 2022

Includes: Supplemental data

Journal Articles

Donor-Derived Adoptive T-Cell Therapy Targeting Multiple Tumor Associated Antigens to Prevent Post-Transplant Relapse in Patients with ALL

Blood (2021) 138 (Supplement 1): 471.

https://doi.org/10.1182/blood-2021-149332

Published: 2021

Journal Articles

Safety and Efficacy of Off-the-Shelf CD30.CAR-Modified Epstein-Barr Virus-Specific T Cells in Patients with CD30-Positive Lymphoma

Blood (2021) 138 (Supplement 1): 1763.

https://doi.org/10.1182/blood-2021-153421

Published: 2021

Journal Articles

Safety and Efficacy Profile of Autologous CD30.CAR-T-Cell Therapy in Patients with Relapsed or Refractory Classical Hodgkin Lymphoma (CHARIOT Trial)

Sairah Ahmed, Ian W. Flinn, Matthew Mei, Peter A. Riedell, Philippe Armand, Natalie S Grover, Andreas Engert, Natalia Lapteva, Paul I. Nadler, Aung Myo, Helen E. Heslop

Blood (2021) 138 (Supplement 1): 3847.

https://doi.org/10.1182/blood-2021-146100

Published: 2021

Journal Articles

Early Signals of Anti-Tumor Efficacy and Safety with Autologous CD5.CAR T-Cells in Patients with Refractory/Relapsed T-Cell Lymphoma

Rayne H. Rouce, LaQuisa C. Hill, Tyler S. Smith, Lina Yang, Blakely Boriskie, Madhuwanti Srinivasan, Huimin Zhang, Silvana Perconti, Birju Mehta, Olga Dakhova, Bambi J. Grilley, Helen E. Heslop, Malcolm K. Brenner, Maksim Mamonkin

Blood (2021) 138 (Supplement 1): 654.

https://doi.org/10.1182/blood-2021-154142

Published: 2021

Journal Articles

Clinical effects of administering leukemia-specific donor T cells to patients with AML/MDS after allogeneic transplant

Blood (2021) 137 (19): 2585–2597.

https://doi.org/10.1182/blood.2020009471

Published: 2021

Includes: Supplemental data

Journal Articles

Treatment of Severe, Drug-Refractory Viral Infections with Allogeneic, Off-the-Shelf Multi-Virus Specific T Cells in Patients Following HSCT: Results from a Phase 2 Study

Ifigeneia Tzannou, MD, Ayumi Watanabe, Bsc, Anastasia Papadopoulou, PhD, Manik Kuvalekar, Msc, Swati Naik, MBBS, Premal Lulla, MBBS, Robert A. Krance, MD, Carlos A. Ramos, MD, Helen E. Heslop, MD DSc, Ann M. Leen, PhD, Bilal Omer, MD

Blood (2020) 136 (Supplement 1): 2–3.

https://doi.org/10.1182/blood-2020-143037

Published: 2020

Journal Articles

Using Allogeneic, Off-the-Shelf, Sars-Cov-2-Specific T Cells to Treat High Risk Patients with COVID-19

Spyridoula Vasileiou, PhD, Manik Kuvalekar, Msc, Aster Workineh, Msc, Ayumi Watanabe, Bsc, Yovana Velazquez, Bsc, Suhasini Lulla, Bsc, Helen E. Heslop, MD DSc, Kimberly Mooney, Bsc, Kevin Grimes, MD, George Carrum, MD, LaQuisa C. Hill, MD, Premal Lulla, MBBS, Ann M. Leen, PhD

Blood (2020) 136 (Supplement 1): 5.

https://doi.org/10.1182/blood-2020-140490

Published: 2020

Journal Articles

A Bank of CD30.CAR-Modified, Epstein-Barr Virus-Specific T Cells That Lacks Host Reactivity and Resists Graft Rejection for Patients with CD30-Positive Lymphoma

David H. Quach, PhD, Haran R. Ganesh, BS, Sachin Thakkar, PhD, Luis Becerra-Dominguez, BS, Birju Mehta, MS, Silvana Perconti, MS, Eric Anderson, BS, Emily M. Hsieh, MD, Olga Dakhova, MD, Huimin Zhang, BS, Bambi J. Grilley, RPh, Malcolm K. Brenner, MD PhD, Helen E. Heslop, MD DSc, Carlos A. Ramos, MD, Rayne H. Rouce, MD, Natalia Lapteva, PhD, Cliona M. Rooney, PhD

Blood (2020) 136 (Supplement 1): 16.

https://doi.org/10.1182/blood-2020-141491

Published: 2020

NARROW

Data mining for second malignancies after CAR-T

Antitumor efficacy and safety of unedited autologous CD5.CAR T cells in relapsed/refractory mature T-cell lymphomas

Introduction to a How I Treat series on emergent CAR T-cell toxicities

Engineering T cells to suppress acute GVHD and leukemia relapse after allogeneic hematopoietic stem cell transplantation

Introduction to a review series on banked allogeneic immune effector cells

CD30.CAR-Modified Epstein-Barr Virus-Specific T Cells (CD30.CAR EBVSTs) Provide a Safe and Effective Off-the-Shelf Therapy for Patients with CD30-Positive Lymphoma

Phase 1b/2 Study of Autologous CD30.CAR-T Cells in Combination with Nivolumab in Patients with Relapsed or Refractory Classical Hodgkin Lymphoma after Failure of Frontline Therapy (ACTION)

Ultrasensitive Circulating Tumor DNA (ctDNA) Dynamics after Autologous CD30.CAR-T Cell Therapy for Relapsed or Refractory (r/r) Classical Hodgkin Lymphoma (CHARIOT Trial)

Updated Results and Correlative Analysis: Autologous CD30.CAR-T-Cell Therapy in Patients with Relapsed or Refractory Classical Hodgkin Lymphoma (CHARIOT Trial)

Tumor-intrinsic causes of CAR-T failure

Long-term follow-up for the development of subsequent malignancies in patients treated with genetically modified IECs

Donor-derived multiple leukemia antigen–specific T-cell therapy to prevent relapse after transplant in patients with ALL

Donor-Derived Adoptive T-Cell Therapy Targeting Multiple Tumor Associated Antigens to Prevent Post-Transplant Relapse in Patients with ALL

Safety and Efficacy of Off-the-Shelf CD30.CAR-Modified Epstein-Barr Virus-Specific T Cells in Patients with CD30-Positive Lymphoma

Safety and Efficacy Profile of Autologous CD30.CAR-T-Cell Therapy in Patients with Relapsed or Refractory Classical Hodgkin Lymphoma (CHARIOT Trial)

Early Signals of Anti-Tumor Efficacy and Safety with Autologous CD5.CAR T-Cells in Patients with Refractory/Relapsed T-Cell Lymphoma

Clinical effects of administering leukemia-specific donor T cells to patients with AML/MDS after allogeneic transplant

Treatment of Severe, Drug-Refractory Viral Infections with Allogeneic, Off-the-Shelf Multi-Virus Specific T Cells in Patients Following HSCT: Results from a Phase 2 Study

Using Allogeneic, Off-the-Shelf, Sars-Cov-2-Specific T Cells to Treat High Risk Patients with COVID-19

A Bank of CD30.CAR-Modified, Epstein-Barr Virus-Specific T Cells That Lacks Host Reactivity and Resists Graft Rejection for Patients with CD30-Positive Lymphoma

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only